Page 4 - Systemic Sclerosis News Today

INSIDE INFORMATION Maintenance of the license isnow subject to the launch of the OATO Phase III before May 2024instead of 31 May 2023 Parties also…

INSIDE INFORMATION Maintenance of the license is now subject to the launch of the OATO Phase III before May 2024 instead of 31 May 2023 Parties also currently negotiating a potential renegotiation... | May 29, 2023

INSIDE INFORMATION Potential license agreement to produce and commercialize original and transformed ALLOB cells BioSenic to potentially receive royalty...

BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces its business update for the first quarter, ended 31 March 2023. Key highlights. Strengthening of Executive Committee and Board of Directors with the ...

Cumberland initiating Phase II FIGHTING FIBROSIS™ clinical trial, Newest program in Cumberlands ifetroban pipeline NASHVILLE, Tenn., May 23, 2023 /PRNewswire/ -- Cumberland... | May 23, 2023

REGULATED INFORMATION ALLOB Phase IIb topline results foreseen in July/August 2023Ongoing discussions for key partnerships with lead clinical assets Mont-Saint-Guibert, Belgium, May 22nd,... | May 22, 2023

INSIDE INFORMATION BioSenic plans to further develop its program on an active injectable viscosupplement JTA, combining anti-pain and anti-inflammatory characteristics on a subtype of knee... | May 17, 2023

REGULATED INFORMATION Preliminary documents for the Annual General Meeting have been made available on company’s website Mont-Saint-Guibert, Belgium, May 15th, 2023 7.00am CET –... | May 15, 2023

Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company, today announced that the Companys product portfolio of FDA-approved brands delivered combined revenues of $9.2 million during the... | May 9, 2023

THREE local veterans have been chosen to compete in an exciting global sporting event this summer.